Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery.

Mesenchymal stromal cells (MSCs) have been proposed for delivering anticancer agents because of their ability to home in on tumor microenvironment. We found that MSCs can acquire strong anti-tumor activity after priming with Paclitaxel (PTX) through their capacity to uptake and then release the drug. Because MSCs secrete a high amount of membrane microvesicles (MVs), we here investigated the role of MVs in the releasing mechanism of PTX. The murine SR4987 line was used as MSC model. The release of PTX from SR4987 in the conditioned medium (CM) was checked by HPLC and the anti-tumor activity of both CM and MVs was tested on the human pancreatic cell line CFPAC-1. MVs were isolated by ultracentrifugation, analyzed by transmission (TEM) and scanning electron microscopy (SEM), and the presence of PTX by the Fourier transformed infrared (FTIR) microspectroscopy. SR4987 loaded with PTX (SR4987PTX) secreted a significant amount of PTX and their CM possessed strong anti-proliferative activity on CFPAC-1. At TEM and SEM, SR4987PTX showed an increased number of "vacuole-like" structures and shed a relevant number of MVs, but did not differ from untreated SR4987. However, SR4987PTX-derived-MVs (SR4987PTX-MVs) demonstrated a strong anti proliferative activity on CFPAC-1. FTIR analysis of SR4987PTX-MVs showed the presence of an absorption spectrum in the corresponding regions of the PTX marker, absent in MVs from SR4987. Our work is the first demonstration that MSCs are able to package and deliver active drugs through their MVs, suggesting the possibility of using MSCs as a factory to develop drugs with a higher cell-target specificity.

[1]  P. Paz,et al.  Exosomes as a Tumor Vaccine: Enhancing Potency Through Direct Loading of Antigenic Peptides , 2003, Journal of immunotherapy.

[2]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[3]  A. Ebrahimi,et al.  Drug Delivery using genetically modified Mesenchymal Stem Cells: A promising targeted-delivery method , 2013 .

[4]  L. Gribaldo,et al.  A mesenchymal stromal cell line resistant to paclitaxel that spontaneously differentiates into osteoblast-like cells , 2011, Cell Biology and Toxicology.

[5]  C. Simón,et al.  Tissue-derived mesenchymal stromal cells used as vehicles for anti-tumor therapy exert different in vivo effects on migration capacity and tumor growth , 2013, BMC Medicine.

[6]  G. Bonadonna,et al.  Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Camussi,et al.  The role of microvesicles in tissue repair , 2011, Organogenesis.

[8]  M. Andreeff,et al.  Concise Review: Dissecting a Discrepancy in the Literature: Do Mesenchymal Stem Cells Support or Suppress Tumor Growth? , 2010, Stem cells.

[9]  D. Scadden,et al.  BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. , 2013, The Journal of clinical investigation.

[10]  R. Schoumacher,et al.  Pancreatic adenocarcinoma in a patient with cystic fibrosis. , 1988, The American journal of medicine.

[11]  Fourier transform infrared microspectroscopy of complex biological systems: from intact cells to whole organisms. , 2012, Methods in molecular biology.

[12]  Stromal-cell and cancer-cell exosomes leading the metastatic exodus for the promised niche , 2013, Breast Cancer Research.

[13]  Johan Skog,et al.  Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers , 2008, Nature Cell Biology.

[14]  Beiyi Shen,et al.  Protein Targeting to Exosomes/Microvesicles by Plasma Membrane Anchors* , 2011, The Journal of Biological Chemistry.

[15]  M. A. Hayat,et al.  Principles and Techniques of Electron Microscopy , 1975 .

[16]  L. Gribaldo,et al.  Expression of B cell markers on SR-4987 cells derived from murine bone marrow stroma. , 1997, Experimental hematology.

[17]  J Ratajczak,et al.  Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication , 2006, Leukemia.

[18]  Alessandro Busca,et al.  Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. , 2009, Journal of the American Society of Nephrology : JASN.

[19]  S. Tatulian,et al.  Infrared spectroscopy of proteins and peptides in lipid bilayers , 1997, Quarterly Reviews of Biophysics.

[20]  Maarten Hulsmans,et al.  MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease. , 2013, Cardiovascular research.

[21]  B. Weaver,et al.  Decoding the links between mitosis, cancer, and chemotherapy: The mitotic checkpoint, adaptation, and cell death. , 2005, Cancer cell.

[22]  R. Schiffelers,et al.  Microvesicles and exosomes: opportunities for cell-derived membrane vesicles in drug delivery. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[23]  S. Gould,et al.  Higher-Order Oligomerization Targets Plasma Membrane Proteins and HIV Gag to Exosomes , 2007, PLoS biology.

[24]  D. Grainger,et al.  A Cell-Based Pharmacokinetics Assay for Evaluating Tubulin-Binding Drugs , 2014, International journal of medical sciences.

[25]  G. Camussi,et al.  Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. , 2013, Stem cells and development.

[26]  E. Parati,et al.  Adipose Tissue-Derived Stromal Cells Primed in Vitro with Paclitaxel Acquire Anti-Tumor Activity , 2013, International journal of immunopathology and pharmacology.

[27]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[28]  E. Parati,et al.  Human skin-derived fibroblasts acquire in vitro anti-tumor potential after priming with Paclitaxel. , 2013, Anti-cancer agents in medicinal chemistry.

[29]  M. Willingham,et al.  Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6α-hydroxytaxol , 1995, Cancer Chemotherapy and Pharmacology.

[30]  S. Lim,et al.  Exosomes for drug delivery - a novel application for the mesenchymal stem cell. , 2013, Biotechnology advances.

[31]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[32]  Seong-Mi Choi,et al.  Mesenchymal stem cell-derived secretome and microvesicles as a cell-free therapeutics for neurodegenerative disorders , 2013, Tissue Engineering and Regenerative Medicine.

[33]  M. Hayat,et al.  Principles and Techniques of Electron Microscopy: Biological Applications , 1973 .

[34]  Y. Jeon,et al.  Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization , 2013, BMC Cancer.

[35]  Philip Siekevitz,et al.  Liver microsomes; an integrated morphological and biochemical study. , 1956 .

[36]  Douglas D. Taylor,et al.  Exosomal microRNA: a diagnostic marker for lung cancer. , 2008, Clinical lung cancer.

[37]  S. Janes,et al.  Stem cells as vectors for antitumour therapy , 2010, Thorax.

[38]  Anna Janowska-Wieczorek,et al.  Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer , 2005, International journal of cancer.

[39]  M. Iannuzzi,et al.  A cystic fibrosis pancreatic adenocarcinoma cell line. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Carroll,et al.  Mesenchymal stromal cells as a drug delivery system , 2009 .

[41]  J. Dayer,et al.  Stimulated T cells generate microparticles, which mimic cellular contact activation of human monocytes: differential regulation of pro‐ and anti‐inflammatory cytokine production by high‐density lipoproteins , 2008, Journal of leukocyte biology.

[42]  K. Shah.  Mesenchymal stem cells engineered for cancer therapy. , 2012, Advanced drug delivery reviews.

[43]  R. Pallini,et al.  Mesenchymal Stromal Cells Primed with Paclitaxel Provide a New Approach for Cancer Therapy , 2011, PloS one.

[44]  T. Simmen,et al.  The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis , 2013, Oncogene.

[45]  L. Hegedũs,et al.  High affinity binding of paclitaxel to human serum albumin. , 2001, European journal of biochemistry.

[46]  P Wadsworth,et al.  Taxol suppresses dynamics of individual microtubules in living human tumor cells. , 1999, Molecular biology of the cell.

[47]  Alessandra Gliozzi,et al.  A Major Role for Side-Chain Polyglutamine Hydrogen Bonding in Irreversible Ataxin-3 Aggregation , 2011, PloS one.

[48]  E. Goormaghtigh,et al.  Attenuated total reflection infrared spectroscopy of proteins and lipids in biological membranes. , 1999, Biochimica et biophysica acta.

[49]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[50]  E. Parati,et al.  Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia‐bearing mice , 2013, British journal of haematology.

[51]  L. Gribaldo,et al.  Establishment and characterization of a new murine cell line (SR-4987) derived from marrow stromal cells , 2006, Cytotechnology.

[52]  J. Freyssinet,et al.  Membrane microparticles: two sides of the coin. , 2005, Physiology.

[53]  D. Prescott,et al.  H3-THYMIDINE DERIVATIVE POOLS IN RELATION TO MACRONUCLEAR DNA SYNTHESIS IN TETRAHYMENA PYRIFORMIS , 1965, Journal of Cell Biology.

[54]  S. Gabrielsson,et al.  Antigen-loaded exosomes alone induce Th1-type memory through a B-cell-dependent mechanism. , 2009, Blood.

[55]  D. Bosnakovski,et al.  Mesenchymal stem cells for anti-cancer drug delivery. , 2013, Recent patents on anti-cancer drug discovery.

[56]  P. Rameshwar.  Mesenchymal Stem Cells can be a Conduit for the Delivery of Therapeutic MicroRNA , 2013 .